Evidence map›Paper›PMID 32830467›Full record

ArticleJournal of Korean medical science2020

Beta-blocker Therapy at Discharge in Patients with Acute Heart Failure and Atrial Fibrillation.

Min Soo Ahn, Byung Su Yoo, Jung Woo Son, Min Heui Yu, Dae Ryong Kang, Hae Young Lee, Eun Seok Jeon, Jae Joong Kim, Shung Chull Chae, Sang Hong Baek and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Korean medical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Min Soo AhnDepartment of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.ORCID https://orcid.org/0000-0001-7896-8175
Byung Su YooDepartment of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea. yubs@yonsei.ac.kr.ORCID https://orcid.org/0000-0002-3395-4279
Jung Woo SonDepartment of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.ORCID https://orcid.org/0000-0002-1790-3228
Min Heui YuCenter of Biomedical Data Science, Yonsei University Wonju College of Medicine, Wonju, Korea.ORCID https://orcid.org/0000-0003-3787-795X
Dae Ryong KangCenter of Biomedical Data Science, Yonsei University Wonju College of Medicine, Wonju, Korea.ORCID https://orcid.org/0000-0002-8792-9730
Hae Young LeeDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0002-9521-4102
Eun Seok JeonDepartment of Internal Medicine, School of Medicine, Sungkyunkwan University, Seoul, Korea.ORCID https://orcid.org/0000-0002-9946-5611
Jae Joong KimDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-2714-2282
Shung Chull ChaeDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.ORCID https://orcid.org/0000-0002-9871-6976
Sang Hong BaekDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-7065-3432
Seok Min KangDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-9856-9227
Dong Ju ChoiDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.ORCID https://orcid.org/0000-0003-0146-2189
Kye Hun KimDepartment of Internal Medicine, Heart Research Center of Chonnam National University, Gwangju, Korea.ORCID https://orcid.org/0000-0002-6885-1501
Myeong Chan ChoDepartment of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea.ORCID https://orcid.org/0000-0002-0047-0227
Seong Yoon KimMetroWest Medical Center, Framingham, MA, USA.ORCID https://orcid.org/0000-0003-0490-0447

Funding

Gangwon branch of the Korean Society of CardiologyKorea Centers for Disease Control and Prevention 2010-E63003-00Korea Centers for Disease Control and Prevention 2011-E63002-00Korea Centers for Disease Control and Prevention 2012-E63005-00Korea Centers for Disease Control and Prevention 2013-E63003-00Korea Centers for Disease Control and Prevention 2013-E63003-01Korea Centers for Disease Control and Prevention 2013-E63003-02Korea Centers for Disease Control and Prevention 2016-ER6303-00Korea Centers for Disease Control and Prevention 2019-ER6303-00
6 · The paper itself

Abstract

backgroundβ-blockers (BBs) are considered primary therapy in stable heart failure (HF) with reduced ejection fraction (HFrEF) without atrial fibrillation (AF); evidence-based benefits of BB on outcome have been documented. However, BBs have not been shown to improve mortality or reduce hospital admissions in HF patients with AF. This study assessed the relationship between BBs at discharge and relevant clinical outcomes in acute heart failure (AHF) patients with AF.

methodsFrom the Korean Acute Heart Failure Registry, 936 HFrEF and 639 HF patients with preserved ejection fraction (HFpEF) and AF were selected. Propensity score (PS) matching accounted for BB selection bias when assessing associations.

resultsBB-untreated patients in the overall cohort of HFrEF and HFpEF had greater deteriorated clinical and laboratory characteristics. In the 670 PS-matched cohort of HFrEF patients, incidences of all clinical events at 60 days and 1 year were not different according to use of BBs. In the 470 PS-matched cohort of HFpEF, rehospitalization and composite outcome at 6 months and 1 year more frequently occurred in non-users of BBs. After adjusting for covariates in the multivariable Cox model of matched cohorts, BB was not associated with clinical outcomes at 60 days and 1 year in HFrEF with AF patients. In HFpEF patients with AF, BB use was associated with reduced 6-month (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.20-0.74) and 1-year rehospitalization (HR, 0.53; 95% CI, 0.34-0.82).

conclusionIn the HFrEF with AF PS-matched cohort, the use of BBs at discharge was not associated with clinical outcome. However, in HFpEF with AF, the use of BB was associated with reduced rehospitalization during the 6-month and 1-year follow up.

Indexed as

Acute DiseaseAdrenergic beta-AntagonistsAgedAtrial FibrillationCohort StudiesFemaleHeart FailureHospitalizationHumansMaleMiddle AgedPatient DischargeProgression-Free SurvivalPropensity ScoreProportional Hazards ModelsRegistriesAdrenergic beta-AntagonistsAtrial FibrillationHeart Failureβ-blocker

Identifiers

PMID32830467
PMCPMC7445305

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.